What does it actually cost a CEO to wait for certainty?

Yi-Kai Lo faced that question while leading Aneuvo through an $8M clinical trial, an 11-month FDA process, and a product failure mid-study. In each case, the decision wasn’t just about risk — it was about whether delay itself had become the bigger risk.

“After analyzing the risk and benefit… the cost of keep delaying the study”

Yi-Kai Lo, CEO of Aneuvo, shares what it takes to lead a medical device company through high-stakes decisions where both action and delay carry real consequences.

From launching a clinical trial before receiving full FDA clarity, to pausing that same study when product quality issues emerged, this episode shows how CEO judgment evolves under pressure. Yi-Kai walks through the tradeoffs behind those decisions — balancing time, capital, regulatory uncertainty, and team alignment.

This is not a story about innovation alone. It’s about how a CEO decides when to move forward, when to stop, and how to align a team when neither option is risk-free.

Key Takeaways (Prioritized)

1. Delay has a measurable cost — not just a perceived risk

When a decision carries an $8M investment and a two-year timeline, waiting for more certainty can become the most expensive option.

2. Alignment comes from framing both sides of the decision

Yi-Kai aligned his team not by pushing forward, but by explicitly weighing risk, benefit, and the cost of delay.

3. Not all decisive action means moving faster

Pausing the clinical trial after product issues emerged was just as critical as launching it early — disciplined stopping is part of execution.

4. Transparency becomes the execution strategy after the decision

Once the study was paused, clear communication with clinical partners and patients became essential to maintaining trust.

5. The right decision depends on the right team at the right stage

Technical problems, regulatory risk, and scaling challenges require different capabilities — building the right team is part of decision-making itself.

Chapter Markers:

00:00 Intro & $8M Clinical Trial Decision

00:46 Meet Yi-Kai Lo & The Story Behind Anuvo

02:05 Why Yi-Kai Chose Startup Life Over Academia

03:09 How Electrical Stimulation Helps Spinal Cord Injuries

06:38 Real Patient Recovery Stories & Mobility Gains

08:46 FDA vs Europe: Different Approval Challenges

10:13 Immediate Improvements Patients Experience

12:16 From Engineer to CEO: Learning Leadership

17:42 The High-Stakes FDA Clinical Trial Gamble

22:18 Pausing a Multi-Million Dollar Study Over Product Issues

29:11 Turning Crisis Into Innovation & Better Products

31:29 The Future of Anuvo & Building the Right Team

Yi-Kai Lo

CEO, Aneuvo

Website: https://aneuvo.com/

LinkedIn: https://www.linkedin.com/in/yi-kai-lo-53531977/

Jeff Holman

Host, The Breakout CEO

https://www.linkedin.com/company/the-breakout-ceo/